Three-month interim report (Q1) 2025 (unaudited)
Company release No. 10/2025
ALK delivers 12% organic revenue growth with operating profit up 50% in Q1
Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including
22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free
cash flow almost tripled. Outlook remains unchanged.
Performance highlights
Comparative figures for Q1 2024 are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated.
Total revenue increased by 12% to DKK 1,522 million (1,351). Europe and International markets delivered growth
rates of 10% and 24% respectively. Revenue in North America bounced back with growth of 14%.
Global tablet sales grew by 22% to DKK 857 million (706) on double-digit growth in all sales regions. European
tablet sales grew by 17%, largely due to increase in new patients, while the positive growth impact of pricing
decreased as anticipated compared to last year.
Global SCIT and SLIT drops sales were unchanged at DKK 500 million (500), while sales of Other products and
services was up 11% to DKK 165 million (145).
Operating profit (EBIT) increased by 50% to DKK 469 million (316), driven by sales growth, improved gross
margin, and cost savings after last year’s optimisation initiatives. The capacity cost-to-revenue ratio was down to
36% (42%). The EBIT margin of 31% (23%) partly reflected that Q1 typically is ALK’s most profitable quarter.
Free cash flow almost tripled to DKK 330 million (111) mainly driven by increased earnings. CAPEX was
unchanged at DKK 57 million (59).
Financial highlights
3M
2025
1,522
469
3M
2024
1,351
316
Growth
(local currencies)
12%
Growth
(reported)
13%
In DKKm
Revenue
EBIT
50%
48%
31%
23%
EBIT margin – %
Allergy+ strategy highlights
The launch of the house dust mite tablet for children positively impacted sales growth in Q1, and initial market
response exceeded expectations. The tablet is currently available for young children in 12 countries.
The tree tablet ITULAZAX® has recently been approved in Europe for treatment of young children and
adolescents aged five to 17.
Efforts to secure market access for the neffy® adrenaline nasal spray is progressing well, and ALK expects the
first launches in Europe to start in Q3 2025. Initial market feedback has been encouraging.
ALK has entered into a four-year agreement with US-based ARS Pharma to co-promote the neffy® adrenaline
(epinephrine) nasal spray in the USA.
The clinical phase 2 of the peanut allergy tablet is on track and patient recruitment continues.
2025 full-year outlook
The full-year outlook remains unchanged, demonstrating a continuous, robust improvement in profitability:
Revenue is still expected to grow by 9-13% driven by growth across all sales regions and product groups. Growth
will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy
immunotherapy (AIT) and anaphylaxis products.
The EBIT margin is still expected to improve by 5 percentage points to around 25%, driven by revenue growth,
improving gross margin, and optimisation efforts.
Commenting on the Q1 results, CEO Peter Halling said: “ALK is off to a very good start in 2025, with sustained
revenue growth, a significant increase in operating profit, and steady progress on our strategic agenda. The initial
market response to the launch of our house dust mite tablet, ACARIZAX®, for use in young children has been
encouraging, and we are excitedly preparing to launch neffy®, the new adrenaline nasal spray. Despite the turmoil in
the markets from trade wars and tariffs, we remain optimistic about the year ahead, anticipating only a modest impact
from tariffs considering our current business footprint."
Page 1 of 16
Company release No 10/2025 – 6 May 2025
ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk.net
Tel +45 4574 7576 – CVR No 63 71 79 16 – LEI code: 529900SGCREUZCZ7P020
